Physician-industry relationship and conflicts of interest: Historical, normative aspects, negative impact and proposals

被引:2
|
作者
Genta-Mesa, Giuseppe [1 ]
Florez, Ivan D. [2 ,3 ]
机构
[1] Univ Antioquia, Fac Med, Secc Pediat Social, Medellin, Colombia
[2] Univ Antioquia, Dept Pediat & Puericultura, Medellin, Colombia
[3] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
关键词
Conflict of Interest; Drug Industry; Medical; Education; Ethics; PHARMACEUTICAL-INDUSTRY; DRUG COMPANIES; PRESCRIBING PATTERNS; DOCTORS; ATTITUDES; PAYMENTS; HEALTH; REPRESENTATIVES; ASSOCIATION; RESIDENTS;
D O I
10.17533/udea.iatreia.16
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This article presents a narrative review of the relationship between physicians and industry (RPI), which includes pharmaceutical, devices and supplements' industries and the conflicts of interest that arise from this relationship. It introduces the problem through some definitions and a brief history review of how RPI has become a major problem in medical practice and health systems. The article discusses the different roles within the most common scenarios in which RPI occurs: biomedical research, clinical practice guidelines, continuing medical education, medical visits, opinion leaders, as well as in direct interaction, indirect exposure, and what we call, an early exposure. Some techniques used by industry to modify prescription habits based on elements of social psychology, are described, as well as the role of gifts and other marketing techniques on prescriptions. We review literature that shows the impact and effect these techniques have on medical practice. Finally, some initiatives, codes and recommendations that have been developed to address the problem and which could contribute to mitigate the negative effects of a very close RPI. The possible actions are: banning any contact between industry and students, inclusion of conflict of interests into the medical curricula, alternative financial support to continuous education, making the disclosure of conflicts of interests mandatory, launching awareness campaings among physicians, and the use of synthesized evidence that have been transparently and independently assessed, among others.
引用
收藏
页码:298 / 310
页数:13
相关论文
共 7 条
  • [1] Physician-industry collaboration: Conflicts of interest and the imputation of motive
    Wadmann, Sarah
    SOCIAL STUDIES OF SCIENCE, 2014, 44 (04) : 531 - 554
  • [2] Counterpoint - Physician-industry relationships can be ethically established, and conflicts of interest can be ethically managed
    White, Andrew P.
    Vaccaro, Alexander R.
    Zdeblick, Thomas
    SPINE, 2007, 32 (11) : S53 - S57
  • [3] Physician-industry conflict of interest: public opinion regarding industry-sponsored research
    Fisher, Charles G.
    DiPaola, Christian P.
    Noonan, Vanessa K.
    Bailey, Christopher
    Dvorak, Marcel F. S.
    JOURNAL OF NEUROSURGERY-SPINE, 2012, 17 (01) : 1 - 10
  • [4] Patient responses to physician disclosures of industry conflicts of interest: A randomized field experiment
    Rose, Susannah L.
    Sah, Sunita
    Dweik, Raed
    Schmidt, Cory
    Mercer, MaryBeth
    Mitchum, Ariane
    Kattan, Michael
    Karafa, Matthew
    Robertson, Christopher
    ORGANIZATIONAL BEHAVIOR AND HUMAN DECISION PROCESSES, 2021, 166 : 27 - 38
  • [5] Conflicts of Interest With the Hand Surgeon's Relationship With Industry
    DelSignore, Jeanne L.
    Goodman, Murray J.
    JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 2012, 37A (01): : 179 - 183
  • [6] Conflicts of interest and clinical drug trials-Impact of the pharmaceutical industry and the impingement on the integrity of medical science
    Ludwig, Wolf-Dieter
    Hildebrandt, Martin
    Schott, Gisela
    ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2009, 103 (03): : 149 - 154
  • [7] Evaluating the relationship between industry sponsorship and conflicts of interest among systematic review authors on treatments for cannabis use disorder
    Carr, Marvin
    Reddy, Vaishnavi
    Anderson, J. Michael
    Weaver, Michael
    Hartwell, Micah
    Vassar, Matt
    SUBSTANCE ABUSE, 2022, 43 (01) : 1180 - 1189